FDA Approves Acadia’s Nuplazid for Parkinson’s Treatment

The FDA April 29 approved Acadia Pharmaceuticals Inc.'s Nuplazid (pimavanserin) for treating hallucinations and delusions associated with psychosis experienced by some Parkinson’s disease patients.

The Food and Drug Administration said this is the first drug it has approved for this indication. As many as 50 percent of Parkinson’s disease patients experience hallucinations or delusions. The agency said “hallucinations and delusions experienced with Parkinson’s disease are serious symptoms, and can lead to thinking and emotions that are so impaired that the people experiencing them may not relate to loved ones well or take appropriate care of themselves.”

“Hallucinations and delusions can ...